Clinical trial
A Phase I/IIA Study to Assess Safety, Tolerability and Preliminary Activity of the Combination of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Patients With Advanced Solid Malignancies (FAK-PD1)
NCT02758587 is registered in ClinicalTrials.gov with NHS Greater Glasgow and Clyde as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/IIA Study to Assess Safety, Tolerability and Preliminary Activity of the Combination of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Patients With Advanced Solid Malignancies (FAK-PD1)
- Lead sponsor
- NHS Greater Glasgow and Clyde
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- July 4, 2017
- Completion date
- December 31, 2021
- Enrollment
- 59 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.